FibroBiologics, Inc. Common Stock
FBLGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Oct 30, 2024 | EF Hutton | Jason Kolbert | $9.00(-84%) | $57.60 | Benzinga |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2026 |
| Maxim Group | downgrade | Buy →Hold | May 4, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2026 |
| D. Boral Capital | downgrade | Buy →Hold | Mar 26, 2026 |
| D. Boral Capital | maintain | Buy | Mar 12, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 26, 2026 |
| D. Boral Capital | maintain | Buy | Feb 25, 2026 |
| D. Boral Capital | maintain | Buy | Jan 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 2, 2026 |
| D. Boral Capital | maintain | Buy | Nov 20, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 5, 2025 |
| D. Boral Capital | maintain | Buy | Nov 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 12, 2025 |
| D. Boral Capital | maintain | Buy | Sep 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 5, 2025 |
| D. Boral Capital | maintain | Buy | Aug 4, 2025 |
| D. Boral Capital | maintain | Buy | Jul 29, 2025 |
| D. Boral Capital | maintain | Buy | Jul 9, 2025 |
| D. Boral Capital | maintain | Buy | Jun 17, 2025 |
| D. Boral Capital | maintain | Buy | May 15, 2025 |
| D. Boral Capital | maintain | Buy | Apr 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2025 |
| D. Boral Capital | maintain | Buy | Apr 1, 2025 |
| D. Boral Capital | maintain | Buy | Mar 4, 2025 |
| D. Boral Capital | maintain | Buy | Feb 27, 2025 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.63| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 31, 2026 | $-0.66 | $-0.93 | — | — |
| Apr 30, 2026 | $-1.33 | $-1.26 | — | — |
| Feb 24, 2026 | $-0.98 | $-1.44 | — | — |
| Oct 31, 2025 | $-2.60 | $-2.00 | — | — |
| Jul 31, 2025 | $-2.40 | $-0.11 | — | — |
| May 14, 2025 | $-2.80 | $-2.00 | — | — |
| Mar 27, 2025 | $-1.80 | $-0.10 | — | — |
| Nov 12, 2024 | $-0.20 | $-1.44 | — | — |
News
Newly Granted Patent Covers Methods of Preparing Fibroblasts to Home to Tumors and Carry Oncolytic Viruses and Other Anti-Cancer Agents HOUSTON, Nov. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has g…
FSdC Spheroids Preserved Disc Height Better Than Any Other Fibroblast-Based Approach Tested in a 12-Week Rabbit Model of Degenerative Disc Disease HOUSTON, Oct. 19, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Nik…
Accepted Patent Contains Claims Covering Methods of Combining Fibroblasts, Platelet Rich Plasma, and Nucleus Pulposus Conditioned Media to Regenerate Cartilage and Improve the Condition of Degenerated and Aged Discs HOUSTON, Oct. 14, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fi…
New approach proposes an alternative to repeated injections HOUSTON, Oct. 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today that it has filed a U.S. patent application covering a new cell-based technology designed to continuously produce…
Newly Granted Patent Covers Methods of Augmenting the Regenerative Efficacy of Fibroblasts Using Platelet Rich Plasma and Cytokines, with Claims Directed to Angiogenesis and Spinal Disc Regeneration HOUSTON, Sept. 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and f…
FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Diseases Transcript
HOUSTON, Sept. 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of a private placement on September 15, 2026, with Hamid Khoja, Ph.D.
Newly Issued Patent Covers Topical Administration of 3D Spheroid Fibroblasts and Fibroblast-Derived Materials to Treat and Accelerate the Healing of Wounds HOUSTON, Sept. 3, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United …
Newly Issued Patent Covers Methods of Promoting Disc Regeneration Using Components Derived from Stimulated Fibroblasts HOUSTON, Sept. 1, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Tr…
FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a topically applied allogeneic cell therapy that uses donor fibroblasts, a type of specialized connective tissue cell, to accelerate wound healing.
HOUSTON, Aug. 27, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the release of the third batch of its CYWC628 drug product and its shipment to Australia in support of the ongoing Phase 1/2 clinical trial in patients wit…
HOUSTON, Aug. 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it received confirmation from The Nasdaq Stock Market LLC ("Nasdaq") on August 25, 2026, informing the Company that it has regained compliance with th…
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widel…
Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc disease HOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the acceptance by IP Australia of Australian Paten…
FibroBiologics Inc. (NASDAQ:FBLG), a clinical-stage biotechnology company, on Tuesday revealed a significant advancement in its orthopedics laboratory.
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte s…
Patent has potential for applications beyond diabetes, including other cell and tissue transplantation procedures HOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO)…